Page 5 - Astrazeneca

Drug major AstraZeneca commits $71 mn to Meghalaya's forestry project

European drug major AstraZeneca has announced a USD 71 million funding to plant and maintain an estimated 64 million plants and trees in the country, primarily in the ecologically fragile Meghalaya. The funding is part of its global forest programme, under which it has committed to plant 200 million trees across six continents by 2030, the company said in a statement on Monday. The company will implement the restoration programme in collaboration with Earthbanc, Earthtree, Worldview Impact India and the Hill Farmers Shiitake Mushroom Coop Society on the Meghalaya Reforestation and Sustainable Livelihoods Project called the Regeneration Meghalaya -- a 30-year regenerative horticulture and agriculture project in the northeastern state. About 200,000 trees have already been planted and with the official project launch, soil and water conservation work is underway to enable further planting of millions of trees in 2024. The project aims to help Meghalayan farmers restore 22,670 hectare

AstraZeneca Pharma India plans to sell its production plant in Bengaluru

AstraZeneca Pharma India plans to sell its production facility in Bengaluru as part of a strategic review of global manufacturing and supply network by its parent, according to a regulatory filing. The company remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes, AstraZeneca Pharma India said in a regulatory filing on Thursday. "As a part of AstraZeneca's ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course," it added. The company will position the manufacturing site for sale in a fully operational manner and begin a search for a buyer who can also act as a contract manufacturing organisation (CMO) for its products currently manufactured or packaged at the site, subject to receipt of necessary statutory approvals, the drug firm said. The company is fully .

Oxford-AstraZeneca covid vaccine faces legal challenge in UK: Report

The Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, is facing a legal challenge in the High Court in London, a UK media report said on Thursday. According to The Daily Telegraph', UK-based pharmaceutical giant AstraZeneca could face a number of further claims based on the outcome of test cases around the condition identified by specialists as Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT), believed to be related to the side effects of the COVID jab. AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects". "The fact of this legal battle poses a fundamental question: in circumstances where individuals are seriously injured or die because of a vaccination recommended by the government should the state provide access to adequate compensation,

Want to eliminate lung cancer as a cause of death: AstraZeneca India MD

The British drug major is developing next-generation vaccines that have the potential to generate potent and long-lasting immune responses

AstraZeneca sues US govt over Medicare drug price negotiation plans

The British drugmaker, which filed its complaint in a Delaware district court, joins other drugmakers and business groups claiming that the program would restrict the development of new medicines

AstraZeneca Pharma India Q1 PAT jumps over two-fold to Rs 53.86 cr

AstraZeneca Pharma India Ltd on Monday reported over two-fold rise in profit after tax at Rs 53.86 crore for the first quarter ended June 30, 2023. The company had posted a profit after tax of Rs 20.15 crore in the same quarter last fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 295.46 crore, as against Rs 232.33 crore in the year-ago period, it added. Total expenses were higher at Rs 232.17 crore, as against Rs 209.14 crore, the company said.

AstraZeneca Pharma India gets GCGI approval to import heart failure drug

AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets. The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing. Dapagliflozin tablets are indicated for the treatment of heart failure in adults, it added. The receipt of this permission paves the way for the launch of the product in India for the specified indication, subject to the receipt of related statutory approvals and licenses, it said. Shares of the company on Monday ended 0.86 per cent down at Rs 3,769.40 apiece on the BSE.

AstraZeneca's cancer drug shows more potential over chemotherapy: Study

The results potentially validate Astra's decision to pay as much as $6 billion for the right to develop the medicine with Daiichi Sankyo Co. and its bet to revive growth a decade ago

Stocks to watch: Adani Enterprises, Tata Motors, NHPC, AstraZeneca, SJVN

Stocks to watch on June 2, 2023: From Adani Enterprises to NHPC, here are top stocks to watch in Friday's trading session

AstraZeneca receives CDSCO's approval for cancer drug Tremelimumab

AstraZeneca Pharma India on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for its cancer drug Tremelimumab Concentrate to be administered intravenously. The approval for Tremelimumab in combination with Durvalumab is based on results from Phase III HIMALAYA clinical trial and is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), the drug firm said. The trial was conducted in 181 centres across 16 countries, including in the US, Canada, Europe, South America and Asia including India, it added. The approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials in India for the specified indication, AstraZeneca Pharma said. "This approval is in line with our ambition of transforming patient outcomes and not leaving any patient behind. We have a breadth of scientific platforms to attack cancer while exploring the po

AstraZeneca Pharma India gets DCGI's nod for cancer-treating drug

AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer. The company said it has been granted approval to import and market trastuzumab deruxtecan used in the treatment of select "HER-2 positive" breast cancer. "The India approval is based on a global, head-to-head, randomised, open label, registrational Phase III trial DESTINY Breast 03. Globally, trastuzumab deruxtecan is approved in more than 40 countries, including the US, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer," AstraZeneca Pharma India said in a statement. HER2 is a form of growth-promoting protein expressed on the surface of multiple tumours, including breast, gastric, lung and colorectal cancers, and is one of the biomarkers expressed in breast cancer tumours, it added. "India's approval of trastuzumab deruxtecan mark

Astrazeneca India to set up five centres for severe asthma management

AstraZeneca India on Tuesday said it will set up five centres across Delhi, Ahmedabad, Goa and Cochin to provide a systematic approach to standardised management of patients with severe asthma. The Centers of Excellence (COEs) would concentrate on specialty and clinical assessment, diagnosis, patient counselling, biologics initiation, and data management related to severe asthma, the drug firm said in a statement. "In India, severe asthma is largely managed by oral glucocorticoids that have side effects such as osteoporosis, hypertension, ulcers, weight gain, etc., despite availability of newer treatment options such as biologicals that have shown to improve outcomes in patients," AstraZeneca India Vice President - Medical Affairs & Regulatory Anil Kukreja said. The company's goal is to establish more such centres of excellence throughout the country and tackle complications by continually monitoring patients, educating healthcare professionals and improving respiratory health for

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

Lynparza is already approved by the FDA to treat a type of breast cancer, ovarian cancer, as well as a different form of prostate cancer

AstraZeneca shot raised heart-related death risk in young women: Report

AstraZeneca's Covid vaccine (manufactured and administered in India as Covishield) raised the risk of heart problem, and death by 3.5 times in young women in the first three months following

AstraZeneca gets CDSCO nod for drug to treat biliary tract cancer

Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary tract cancer (BTC) in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab, the drug firm said in a statement. BTC is a group of rare and aggressive gastrointestinal (GI) cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine). Apart from ampullary cancer, early-stage BTC often presents without clear symptoms and most new cases of BTC are therefore diagnosed at an advanced stage, when treatment options are limited, and the prognosis is poor. More than 30,000 new cases of BTC are seen in India every year with 90 per cent of them diagnosed in the advanced stage. "The approval underpins our commitment to transform patient outcomes by harnessing the power of science

AstraZeneca Pharma India's MD resigns; appoints Sanjeev Panchal for 3 years

AstraZeneca Pharma India on Wednesday said Gagandeep Singh Bedi has resigned from the post of managing director. The drug firm said it has approved the appointment of Sanjeev Panchal as its managing director for a period of three years with effect from January 1, 2023. Panchal had joined AstraZeneca Pharma in February 2003 as Brand Associate and progressed through several positions in India, Indonesia, Asia Pacific and the international region, based in Singapore and the United Kingdom (UK), it said.

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Woman slips into coma after AstraZeneca vaccine dose against Covid-19

Diagnosed with rare, serious condition

Stocks to Watch: Zomato, SBI, Adani Group, Britannia, ONGC, Gland Pharma

Stocks to Watch Today: According to reports, Zomato is likely to witness a block deal on Wednesday.

AstraZeneca India gets regulator's approval to market anti-diabetes drug

Drug firm AstraZeneca India on Tuesday said it has received approval from the country's drug regulator to market anti-diabetes medication Dapagliflozin. The company said it has received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD). Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said. The approval is applicable for both diabetic and non-diabetic CKD patients, it added. CKD is one of the leading causes of hospitalisation globally and in India, representing a significant clinical and economic burden. "The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country .